Literature DB >> 24709784

Independent pretreatment predictors of Graves' disease outcome.

Dalia Daukšienė1, Albertas Daukša, Narseta Mickuvienė.   

Abstract

BACKGROUND AND OBJECTIVE. Current treatment options of Graves' disease (GD) are often unsatisfactory. This study aimed at determining the independent baseline predictors of medical treatment failure in GD. MATERIAL AND METHODS. A retrospective study of 194 patients with GD was carried out. According to the disease outcome, patients were divided into groups. The remission group included the patients who achieved long-term remission after initial antithyroid drug (ATD) treatment with no relapse (group 1) or after 2 or 3 courses of ATD therapy (group 2). The treatment failure group included the patients who underwent thyroid ablation due to relapse (group 3) or without ATD withdrawal (group 4). RESULTS. A family history of thyroid disorders was associated with greater odds of failure (P=0.046). Higher thyrotropin receptor antibodies (TRAb) levels and a larger goiter size (grade 2/grade 3) at the onset of the disease were both independently associated with a greater likelihood of failure. The initial TRAb concentration of 30.2 U/L and the TRAb concentration of 12.97 U/L at the end of ATD therapy were found to be the best cutoff values predicting the treatment failure. A hypoechogenic thyroid after ATD therapy, but not before therapy, increased the likelihood of failure by nearly 7.5 times (P<0.001). CONCLUSIONS. Higher TRAb levels and a larger goiter size at the onset of the disease were found to be the independent predictors of medical treatment failure in GD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24709784

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  4 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

2.  Epidemiology, management and outcomes of Graves' disease-real life data.

Authors:  Y S Hussain; J C Hookham; A Allahabadia; S P Balasubramanian
Journal:  Endocrine       Date:  2017-05-06       Impact factor: 3.633

3.  Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.

Authors:  Hua Yang; Yilei Cong; Tengfei Wu; Hong Tang; Muhao Ma; Juanhua Zeng; Wenya Zhang; Zhen Lian; Xinyu Yang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

4.  Mean Platelet Volume in Graves' disease: A Sign of Hypermetabolism Rather than Autoimmunity?

Authors:  Gulay Simsek Bagir; Filiz Eksi Haydardedeoglu; Okan Sefa Bakiner; Emre Bozkirli; Melek Eda Ertorer
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.